Gwo Xi Stem Cell Applied Technology Co. , Ltd

Gwo Xi Stem Cell Applied Technology Co., Ltd develops stem cell technology for patients with unmet medical needs. Its pipeline includes GXHPC1, an autologous adipose-derived stem cell therapy in phase II clinical trials for liver cirrhosis, and GXNPC1, an autologous adipose-derived stem cell therapy in phase II clinical trials for chronic stroke. The company is also developing GXCPC1, an allogeneic adipose-derived stem cell therapy in phase I/II clinical trials for osteoarthritis, and GXIPC1, an allogeneic adipose-derived stem cell therapy in phase I clinical trials for diabetes. Founded in 2011, the company is based in Zhubei, Taiwan.